Novel Strategy for HIV Drug Resistance Monitoring in Developing Countries


Principal Investigator:
Christopher Rowley, Research Associate in the Department of Immunology and Infectious Diseases

Immunology+Infectious Diseases Prime

Dates of Research:
June 20, 2011 — May 31, 2012


The increase in antiretroviral use globally to treat HIV infections has been a much needed and worthy achievement as many thousands of lives have been saved by the rapid expansion of treatment. A natural byproduct of the increased use of these medications is the acquisition of drug resistance in patients failing therapy that will ultimately result in transmitted drug resistance. The timing of the increase in transmitted resistance, so that it impacts national antiretroviral therapy (ART) programs, is unclear, but in resource-limited regions, where it is not feasible to test all individuals for drug resistance at the time they enter care, alternative strategies to monitor resistance are needed. We hypothesize that transmitted drug resistance can be monitored with novel strategies in Botswana.